In the spirit of World Cup competition, we're holding our own tournament in search of the Better Stock Today. We're pitting 32 companies against each other and you, the reader, will determine the winner.
Motley Fool health care analyst David Williamson makes the case for Gilead to win this match up. He believes Gilead's Sovaldi will continue to beat analyst estimates and that its runaway success will continue. Estimated to do $1.4 billion in 1st quarter sales, the instant blockbuster clocked in at $2.3 billion. Gilead already has an even better combo treatment in the works and despite its high price tag, Gilead's future rivals don't appear willing to undercut its cost. With an estimated 150 million hepatitis-c cases worldwide, curing the disease will prove beneficial to humanity and Gilead shareholders.
Financials analyst Tyler Riggs believes that the biggest reason Citigroup is the strongest buy in the field is because Wall Street has got it all wrong. Instead of following the herd and focusing on just two numbers – top line revenues and bottom line earnings – savvy investors are reading between the lines on this company and finding an incredibly efficient core banking operation that's thriving. Add Citigroup's unmatched international reach to the equation, and you've got a huge opportunity to get in before Wall Street realizes what they're missing.
Vote here to determine the winner of this match and sound off in the comments. Check back to Fool.com to see who advances in the tournament.
David Williamson has no position in any stocks mentioned. Tyler Riggs has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences. The Motley Fool owns shares of Citigroup and Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.